Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Divergent synthesis of a pochonin library targeting HSP90 and in vivo efficacy of an identified inhibitor.

× No keyword cloud information.

35 in total

Review 1. Tumor selectivity of Hsp90 inhibitors: the explanation remains elusive.

Authors: Gabriela Chiosis; Len Neckers
Journal: ACS Chem Biol Date: 2006-06-20 Impact factor: 5.100

2. A small molecule designed to bind to the adenine nucleotide pocket of Hsp90 causes Her2 degradation and the growth arrest and differentiation of breast cancer cells.

Authors: G Chiosis; M N Timaul; B Lucas; P N Munster; F F Zheng; L Sepp-Lorenzino; N Rosen
Journal: Chem Biol Date: 2001-03

3. Geldanamycin activates a heat shock response and inhibits huntingtin aggregation in a cell culture model of Huntington's disease.

Authors: A Sittler; R Lurz; G Lueder; J Priller; H Lehrach; M K Hayer-Hartl; F U Hartl; E E Wanker
Journal: Hum Mol Genet Date: 2001-06-01 Impact factor: 6.150

4. Sensitivity of mature Erbb2 to geldanamycin is conferred by its kinase domain and is mediated by the chaperone protein Hsp90.

Authors: W Xu; E Mimnaugh; M F Rosser; C Nicchitta; M Marcu; Y Yarden; L Neckers
Journal: J Biol Chem Date: 2000-11-08 Impact factor: 5.157

5. Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2.

Authors: Andrea D Basso; David B Solit; Pamela N Munster; Neal Rosen
Journal: Oncogene Date: 2002-02-14 Impact factor: 9.867

Review 6. Geldanamycin as a potential anti-cancer agent: its molecular target and biochemical activity.

Authors: L Neckers; T W Schulte; E Mimnaugh
Journal: Invest New Drugs Date: 1999 Impact factor: 3.850

7. BCR-ABL point mutants isolated from patients with imatinib mesylate-resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein 90.

Authors: Mercedes E Gorre; Katharine Ellwood-Yen; Gabriela Chiosis; Neal Rosen; Charles L Sawyers
Journal: Blood Date: 2002-10-15 Impact factor: 22.113

8. Roles of heat-shock protein 90 in maintaining and facilitating the neurodegenerative phenotype in tauopathies.

Authors: Wenjie Luo; Fei Dou; Anna Rodina; Sophorn Chip; Joungnam Kim; Qi Zhao; Kamalika Moulick; Julia Aguirre; Nian Wu; Paul Greengard; Gabriela Chiosis
Journal: Proc Natl Acad Sci U S A Date: 2007-05-21 Impact factor: 11.205

Review 9. Drugging the cancer chaperone HSP90: combinatorial therapeutic exploitation of oncogene addiction and tumor stress.

Authors: Paul Workman; Francis Burrows; Len Neckers; Neal Rosen
Journal: Ann N Y Acad Sci Date: 2007-05-18 Impact factor: 5.691

10. Halohydrin and oxime derivatives of radicicol: synthesis and antitumor activities.

Authors: Tsutomu Agatsuma; Harumi Ogawa; Kazuhito Akasaka; Akira Asai; Yoshinori Yamashita; Tamio Mizukami; Shiro Akinaga; Yutaka Saitoh
Journal: Bioorg Med Chem Date: 2002-11 Impact factor: 3.641

16 in total

1. The novel Hsp90 inhibitor NXD30001 induces tumor regression in a genetically engineered mouse model of glioblastoma multiforme.

Authors: Haihao Zhu; Steve Woolfenden; Roderick T Bronson; Zahara M Jaffer; Sofia Barluenga; Nicolas Winssinger; Allan E Rubenstein; Ruihong Chen; Al Charest
Journal: Mol Cancer Ther Date: 2010-07-19 Impact factor: 6.261

2. Insights into radicicol biosynthesis via heterologous synthesis of intermediates and analogs.

Authors: Hui Zhou; Kangjian Qiao; Zhizeng Gao; John C Vederas; Yi Tang
Journal: J Biol Chem Date: 2010-10-20 Impact factor: 5.157

3. Heat shock protein 90 inhibition: rationale and clinical potential.

Authors: Robert B Den; Bo Lu
Journal: Ther Adv Med Oncol Date: 2012-07 Impact factor: 8.168

4. A novel small molecule HSP90 inhibitor, NXD30001, differentially induces heat shock proteins in nervous tissue in culture and in vivo.

Authors: Jieun R C Cha; Kyle J H St Louis; Miranda L Tradewell; Benoit J Gentil; Sandra Minotti; Zahara M Jaffer; Ruihong Chen; Allan E Rubenstein; Heather D Durham
Journal: Cell Stress Chaperones Date: 2013-10-03 Impact factor: 3.667

Review 5. Impact of heat-shock protein 90 on cancer metastasis.

Authors: Shinji Tsutsumi; Kristin Beebe; Len Neckers
Journal: Future Oncol Date: 2009-06 Impact factor: 3.404

6. Therapeutic potential of HSP90 inhibition for neurofibromatosis type 2.

Authors: Karo Tanaka; Ascia Eskin; Fabrice Chareyre; Walter J Jessen; Jan Manent; Michiko Niwa-Kawakita; Ruihong Chen; Cory H White; Jeremie Vitte; Zahara M Jaffer; Stanley F Nelson; Allan E Rubenstein; Marco Giovannini
Journal: Clin Cancer Res Date: 2013-05-28 Impact factor: 12.531

7. Synthesis and SAR study of N-(4-hydroxy-3-(2-hydroxynaphthalene-1-yl)phenyl)-arylsulfonamides: heat shock protein 90 (Hsp90) inhibitors with submicromolar activity in an in vitro assay.

Authors: Thota Ganesh; Pahk Thepchatri; Lian Li; Yuhong Du; Haian Fu; James P Snyder; Aiming Sun
Journal: Bioorg Med Chem Lett Date: 2008-08-14 Impact factor: 2.823

8. Inhibition of HSP90 with pochoximes: SAR and structure-based insights.

Authors: Sofia Barluenga; Jean-Gonzague Fontaine; Cuihua Wang; Kais Aouadi; Ruihong Chen; Kristin Beebe; Len Neckers; Nicolas Winssinger
Journal: Chembiochem Date: 2009-11-23 Impact factor: 3.164

9. The HSP90 binding mode of a radicicol-like E-oxime determined by docking, binding free energy estimations, and NMR 15N chemical shifts.

Authors: Martin Spichty; Antoine Taly; Franz Hagn; Horst Kessler; Sofia Barluenga; Nicolas Winssinger; Martin Karplus
Journal: Biophys Chem Date: 2009-04-15 Impact factor: 2.352

10. The Hsp90 mosaic: a picture emerges.

Authors: Matthias P Mayer; Chrisostomos Prodromou; Judith Frydman
Journal: Nat Struct Mol Biol Date: 2009-01 Impact factor: 15.369